Aligos Therapeutics (ALGS) to Release Earnings on Tuesday

Aligos Therapeutics (NASDAQ:ALGS) will post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Aligos Therapeutics to post earnings of ($0.19) per share for the quarter.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The firm had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative return on equity of 116.41%. On average, analysts expect Aligos Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS opened at $0.81 on Friday. The business has a 50-day moving average of $0.92 and a 200-day moving average of $0.76. The stock has a market capitalization of $61.30 million, a price-to-earnings ratio of -0.51 and a beta of 2.37. Aligos Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.38.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).